Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
From MaRDI portal
Publication:4670477
Recommendations
- Sequential designs for dose escalation studies in oncology
- Optimal sequential designs in phase I studies
- Sequential designs for ordinal phase I clinical trials
- scientific article; zbMATH DE number 3856244
- Designs for phase II trials with trade-of between efficacy and toxicity
- Designs for Group Sequential Phase II Clinical Trials
- Sequential experimentation in clinical trials. Design and analysis
Cites work
- A Random Walk Rule for Phase I Clinical Trials
- Consistency of continual reassessment method under model misspecification
- Continual Reassessment Method: A Likelihood Approach
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Cited in
(53)- Bayesian models and decision algorithms for complex early phase clinical trials
- Impact of different model structure and prior distribution in continual reassessment method
- Joint modelling of recurrence and progression of adenomas: a latent variable approach
- A simple technique to evaluate model sensitivity in the continual reassessment method
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
- Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- The adaptive accelerated biased coin design for phase I clinical trials
- Ethical issues in oncology biostatistics
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
- Unifying CRM and EWOC designs for phase I cancer clinical trials
- Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long‐Term Binary Endpoint
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
- DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
- A simulation-free approach to assessing the performance of the continual reassessment method
- Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
- Cumulative cohort design for dose-finding
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Risk-group-specific dose finding based on an average toxicity score
- CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
- Early completion of phase I cancer clinical trials with Bayesian optimal interval design
- Seamless phase I/II design for novel anticancer agents with competing disease progression
- A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
- Extending the continual reassessment method to accommodate step-up dosing in phase I trials
- Dose finding studies for therapies with late-onset toxicities: a comparison study of designs
- Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
- Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer
- A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering
- Adaptive clinical trial designs for phase I cancer studies
- SEQUENTIAL METHODS IN CLINICAL TRIALS*
- A weighted zero-inflated Poisson model for estimation of recurrence of adenomas
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
- Monitoring the rates of composite events with censored data in phase II clinical trials
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Target toxicity design for phase I dose-finding
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Monitoring late-onset toxicities in phase I trials using predicted risks
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Handbook of statistics in clinical oncology
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
This page was built for publication: Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4670477)
